Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape

Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc SNDX with a BUY rating and a price target of $40.

SNDX's lead asset and principal value driver is revumenib, an inhibitor of menin in development for a genetically defined subset of leukemias that currently have no FDA-approved targeted therapies. 

The analyst says Syndax's revumenib is the most advanced and potentially best-in-class menin inhibitor in development for hematological and solid cancers in a crowded, competitive landscape. 

The analyst also writes that the ongoing investor debates around menin inhibitors provide meaningful upside opportunity as revumenib heads into a catalyst-rich ~12 months, which includes potentially stock-moving topline registrational data in late-line KMT2Ar (3Q23) and mNPM1 (2024) acute leukemias as well as initial proof-of-concept data in treatment-naïve AML (YE23) and solid tumors (MSS CRC in YE23). 

The company's second program axatilimab partnered with Incyte Pharmaceutical Inc INCY, is a partially de-risked and underappreciated asset.

The analyst says the price target reflects 80% PoS for revumenib in R/R acute leukemias and 75% PoS for axatilimab for 3L cGVHD, with additional contributions from probability-adjusted revenues in the frontline settings for both agents.

Price Action: SNDX shares are up 0.20% at $20.32 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CareInitiationSmall CapAnalyst RatingsTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!